Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
15.22
-0.11 (-0.72%)
At close: Apr 28, 2026, 4:00 PM EDT
15.30
+0.08 (0.53%)
After-hours: Apr 28, 2026, 4:57 PM EDT
Mesoblast Employees
Mesoblast had 81 employees as of June 30, 2025. The number of employees increased by 8 or 10.96% compared to the previous year.
Employees
81
Change (1Y)
8
Growth (1Y)
10.96%
Revenue / Employee
$807,210
Profits / Employee
-$1,165,062
Market Cap
2.00B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Adaptive Biotechnologies | 624 |
| Galapagos NV | 558 |
| Ocular Therapeutix | 325 |
| Syndax Pharmaceuticals | 298 |
| Zymeworks | 264 |
| Capricor Therapeutics | 231 |
| Stoke Therapeutics | 170 |
MESO News
- 13 days ago - Mesoblast Acquires CAR Technology From Mayo Clinic To Enhance MSC Therapies - Nasdaq
- 13 days ago - Mesoblast Secures Exclusive CAR-MSC Technology License; Stock Up - Nasdaq
- 13 days ago - Mesoblast (MESO) Secures Global License for Advanced CAR Technology - GuruFocus
- 13 days ago - Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products - GlobeNewsWire
- 18 days ago - Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION - GlobeNewsWire
- 20 days ago - Mesoblast (MESO) Gains on FDA Clearance for Duchenne Therapy Study - GuruFocus
- 20 days ago - Mesoblast Ltd Investor Day Transcript - GuruFocus
- 20 days ago - Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation - GlobeNewsWire